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BK polyomavirus (BKPyV) was isolated in 1971 from the urine of a kidney transplant 
patient. Soon after its identification, BKPyV was characterized as a kidney-tropic virus, 
which is responsible of a significant fraction of the rejection of transplant kidney in the 
host. Moreover, in experimental conditions, BKPyV is able to transform different types 
of animal and human cells and to induce tumors of different histotypes in experimental 
animals. BKPyV DNA sequences have been detected in healthy individuals and cancer 
patients using polymerase chain reaction/Shouthern blot hybridization methods. Serum 
antibodies against this polyomavirus were revealed using immunological techniques, 
which, however, cross-react with other polyomaviruses such as JC (JCPyV) and Simian 
Virus 40. These non-specific data indicate the need of novel immunological methods 
and new investigations to check in a specific manner, BKPyV spread in humans. To 
this aim, mimotopes from BKPyV structural capsid protein 1 (VP1) were employed for 
specific immunological reactions to IgG antibodies of human serum samples. An indirect 
enzyme-linked immunosorbent assay with synthetic peptides mimicking immunogenic 
epitopes of BKPyV VP1 was set up and employed to test sera of healthy adult subjects. 
Data from this innovative immunological assay indicate that serum antibodies against 
BKPyV VP1 mimotopes are detectable in healthy subjects ranging from 18 to 90 years 
old. The overall prevalence of serum samples that reacted to BKPyV VP1 mimotopes 
was 72%. The strong points from this investigation are the novelty of the immunological 
method, its simplicity of the approach, and the specificity of BKPyV antibody reaction to 
VP1 mimotopes.
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inTrODUcTiOn
BK polyomavirus (BKPyV) was isolated in 1971 by Gardner et al. from the urine of a renal transplant 
patient (1). Soon after its identification, BKPyV was characterized as a human polyomavirus (HPyV) 
with a circular double-stranded DNA of about 5.15  Kb (2). In experimental conditions, BKPyV 
is able to transform human cells of different types and to induce tumors of different histotypes in 
experimental animals (3).
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In most cases, BKPyV primary infection occurs during child-
hood (2). However, some investigations shown that BKPyV could 
even be vertically transmitted from mother to embryo/fetus (4).
Many reports have indicated a high prevalence of serum 
IgG antibodies against BKPyV in different human populations 
worldwide (2, 5, 6), suggesting that BKPyV is a ubiquitous HPyV.
After primary infection, BKPyV remains in the human host 
lifelong as a latent/persistent infection. BKPyV may reactivate in 
immunocompromised patients or during immune depression. In 
bone marrow and kidney transplant patients, BKPyV infection 
may cause hemorrhagic cystitis and kidney rejection (7, 8).
Many studies have reported an association between BKPyV 
and diseases of the urinary, genital, or upper respiratory tracts. 
BKPyV footprints have been detected at high prevalence in 
cancers of different histotypes, such as brain, bone, prostate, insu-
linoma, Kaposi’s sarcomas, urinary, and genital tumors (3). In a 
2012 meeting organized by the World Health Organization, held 
in Lyon, France, BKPyV was classified as “possibly carcinogenic 
to humans” (9).
BK polyomavirus encodes two viral oncogenes, the large T 
antigen (Tag) and small Tag (tag), which transform different types 
of animal and human cells. Specifically, Tag binds and abolishes 
the functions of tumor suppressor p53 and pRB family proteins. 
Tag is also clastogenic and mutagenic. Small tag interacts with 
phosphatase PP2A, which activates the Wnt pathway. Moreover, 
tag activates phosphatidylinositol 3-kinase, an enzyme involved 
in pathways crucial for cell proliferation and transformation. 
These Tag and tag activities are able to adversely affect the cel-
lular genome where gene mutations may accumulate. Due to Tag 
binding, in the absence of p53 functions, the cellular DNA then 
remains unrepaired and consequently the genome “derails” (3, 
10). In addition, it has been shown that, in prostate carcinoma 
(PCa), loss-of function mutations in the p53 gene at very early 
stages are rare. Therefore, the sequestration of wild-type p53 
exerted by BKPyV Tag oncoprotein is considered a hallmark for 
BKPyV involvement, during initial phases (11). These mecha-
nisms may ensure PCa genetic heterogeneity. However, at present, 
there are insufficient human epidemiological data to support this 
hypothesis (10). Considering that BKPyV infection is ubiquitous 
in the general population with a prevalence of serum antibodies 
against this polyomavirus of up to 90% worldwide (2, 5, 6), it 
is difficult to assess whether this virus has a specific role of in 
cellular transformation (12).
BK polyomavirus is the causal agent of polyomavirus-
associated nephropathy. Indeed, up to 36% of kidney transplant 
patients are at risk of premature allograft failure (13). At-risk 
patients can be identified before significant functional impair-
ment of the renal allograft occurs (13–17). For this reason, the 
study of more precise and advanced techniques detecting BKPyV 
infection and reactivation is important.
Taken overall, these data prompted us to develop and set up 
a new indirect enzyme-linked immunosorbent assay (ELISA) 
in order to determine BKPyV antibody and its titer. Until now, 
immunological methods mainly employed virus-like particles 
(VLPs)/recombinant viral protein (VP) 1 (VP1) as antigens. 
Data obtained using these approaches were always influenced by 
some cross-reactivity among the three polyomaviruses BKPyV, 
JCPyV, and Simian Virus 40 (SV40) (18). Indeed, BKPyV displays 
strong antigenic homology with JCPyV and SV40 (6, 19, 20). In 
this study, a specific sensitive innovative indirect ELISA with 
synthetic peptides was employed to test BKPyV spread in healthy 
adult subjects.
MaTerials anD MeThODs
human samples
Serum samples (n = 446) were collected from healthy subjects 
(HSs), mean age =  49.73, at the Clinical Laboratory Analysis, 
University Hospital of Ferrara. Sera were taken from discarded 
laboratory analysis samples, after routine analyses at the 
University Hospital, Ferrara, Italy, before their destruction by 
incineration. The hospital records annotated these serum samples 
as belonging to HS. Indeed, parameters of blood analyses were all 
in the normal index range.
Sera were collected anonymously, coded with indications of 
age and gender only. The County Ethical Committee, Ferrara 
approved the project. Written informed consent was obtained 
from all participants at the time of the hospital admission. All 
serum samples were stored at −20°C until testing.
synthetic Peptides
Computer-assisted analyses enabled two specific BKPyV pep-
tides to be selected from the late viral region by comparing VP1 
proteins from BKPyV, with amino acids from JCPyV and SV40 
polyomaviruses, which are highly homologous to BKPyV, as well 
as with other less homologous polyomaviruses (http://blast.ncbi.
nlm.nih.gov; Figure  1; Figure S1 in Supplementary Material). 
Preliminary ELISA results indicated that the two peptides did 
not cross-react with the SV40 and JCPyV hyperimmune sera 
employed (see data in the Section “Results”). The amino acid 
(a.a.) sequences of the two peptides, known as VP1-L and VP1-
M, which start at the N-terminal with a.a. L and M, respectively, 
are as follows:
VP1-L: NH2—LKLSAENDFSSDSPERK—COOH
VP1-M: NH2—MLNLHAGSQKVHEHGGGK—COOH
Amino acid sequences of BKPyV viral capsid protein 1 (VP1), 
named peptide L viral capsid protein 1 (VP1 L) and VP1 peptide 
M (VP1 M), were characterized regarding stable secondary 
structure formation. Analysis was carried out by PSIPRED server 
(21–23). Moreover, peptide sequences were mapped on native 
virion proteins to verify structural similarities. VP1-L and VP1-
M, in their monomeric forms, were obtained from computational 
prediction carried out by I-TASSER server (24–26). Molecular 
visualizations were performed by PyMOL (PyMOL Molecular 
Graphics System, Version 1.3, Schrödinger, LLC). Computational 
tools were available through ExPASy server (27).
indirect elisa
Indirect ELISA was developed and standardized to detect specific 
antibodies against BKPyV VP1 in human sera using VP1-L and 
VP1-M synthetic peptides.
FigUre 1 | similarity among BK polyomavirus (BKPyV)-specific VP1 mimotopes, VP1l (a) and VP1M (B) and other polyomavirus VP1. Amino acid (a.a.) 
sequences of two different peptides of viral protein 1 (VP1) of BKPyV. The peptides were selected on the basis of their low homology with the corresponding 
peptides of other polyomaviruses. Preliminary enzyme-linked immunosorbent assay indicated that only VP1 L and VP1 M peptides reacted with human serum 
antibodies without cross-reaction with JCPyV and SV40 immune-sera employed as controls. Similarity between synthetic peptides specific to BKPyV and other 
polyomavirus a.a. sequences: simian virus 40 (SV40), human polyomavirus JC (JCPyV), simian virus 12 (SV12), human polyomavirus 12 (HPyV12), trichodysplasia 
spinulosa-associated polyomavirus (TSPyV), human polyomavirus 9 (HPyV 9), B-lymphotropic polyomavirus (LPV), Merkel cell polyomavirus (MCPyV), human 
polyomavirus KI (KIPyV), human polyomavirus WU (WUPyV), Saint Louis polyomavirus (STLPyV), Malawi polyomavirus/human polyomavirus 10 (HPyV10), human 
polyomavirus 7 (HPyV 7), New Jersey polyomavirus/human polyomavirus 13 (NJPyV), and human polyomavirus 6 (HPyV 6).
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Peptide Coating
Plates were coated with 5  μg of the selected peptide for each 
well and diluted in 100 μl of Coating Buffer (Candor Bioscience, 
Wangen im Allgäu, Germany) at 4°C for 16 h.
Peptide Blocking
Blocking was made with 200  μl/well of the Blocking Solution 
(Candor Bioscience, Germany) at 37°C for 90 min.
Primary Antibody Adding
Wells were covered with 100 μl of serum sample diluted 1/20 in 
low cross-buffer (Candor Bioscience, Germany). Different wells 
were covered with different kind of serum samples: (1) the BKPyV 
positive-control, represented by immune rabbit serum containing 
anti-BKPyV antibodies; (2) the negative controls represented 
by immune sera anti-SV40 and anti-JCPyV; (3) human serum 
samples, which were found to be BKPyV-negative in previous 
investigation using the hemagglutination inhibition (HAI) assay. 
Each sample was analyzed three times in duplicate wells.
Secondary Antibody Adding
The solution contained a goat anti-human or anti-rabbit IgG 
heavy and light chain specific peroxidase-conjugate (Calbiochem-
Merck, Darmstadt, Germany) diluted 1:10,000 in low cross-buffer.
Dye Treatment and Spectrophotometric Reading
Samples were treated with 100 μl of 2,2′-azino-bis 3-ethylben-
zthiazoline-6-sulfonic acid solution (Sigma-Aldrich, Milan, 
Italy), for 45 min. at RT and then read on the spectrophotometer 
(Thermo Electron Corporation, model Multiskan EX, Helsinki, 
Finland) at a wavelength (λ) of 405 nm. The color intensity in 
wells where the immunocomplexes were formed was determined 
by optical density (OD).
Cutoff Determination
Cutoff values were determined for each assay using the OD read-
ing of the three negative control sera that were added to the SD and 
multiplied three times (+3SD). The three BKPyV negative control 
sera were selected from those below the cutoff value determined 
with second-degree polynomial regression by plotting the ranked 
net OD individual values for each peptide. A tendency curve was 
drawn from a second-degree polynomial regression for VP1 L 
and M peptides, as published before for MCPyV and BKPyV VLP 
(28, 29).
Sera with antibodies against BKPyV were considered 
VP-positive upon reacting to both peptides of the late region and 
when sera that had been analyzed three times by indirect ELISA 
testing gave the same positive results.
BKPyV hemagglutination (ha) and hai 
assays
A BKPyV viral working stock, Gardner strain (1, 19), for the HAI 
assay was obtained from infected Vero cells (African green mon-
key kidney cells, ATCC catalog number CRL-1587) as described 
before (19, 30, 31). The viral titer, determined by HA assay, was 
1.6 ×  102 hemagglutinating units, corresponding to 1.6 ×  106 
plaque-forming units (PFUs)/ml (19). BKPyV was employed as 
antigen in both HA and HAI assays.
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BK polyomavirus HA and HAI titrations were carried out 
as described in detail elsewhere (19, 30, 31). The HA titer was 
calculated based on the highest virus dilution that gave complete 
HA. The HAI assay allows the detection of serum antibodies 
against the polyomavirus BKPyV, which abolish its agglutination 
property. The HAI titer was defined as the highest dilution of each 
serum sample that inhibited viral HA completely.
BKPyV neutralization assay with human 
serum samples
Permissive Vero cells were used as described and modified slightly 
as follows: cells were grown and propagated in BioWhittaker® 
RPMI 1640 with l-glutamine medium (RPMI), supplemented 
with 10% fetal bovine serum (FBS) at 37°C in a humidified 
atmosphere with 5% CO2 (19). BKPyV infectivity neutraliza-
tion was carried out by incubating each human serum, diluted 
at 1:20 in phosphate-buffered saline (PBS) with 5 × 106 PFU of 
BKPyV at 37°C for 30 min. Then, the suspension was added to 
Vero cell monolayers for 2 h at 37°C. The inoculum was removed, 
cells were washed three times with RPMI, and overlaid with the 
medium containing 1% FBS. Infected Vero cell monolayers were 
maintained in RPMI + 1% FBS for 3 weeks, until cytopathic effect 
(CPE) appearance (19, 32). Each sample was tested in duplicate 
and with different sera with distinct levels of antibodies (OD 
reading). The neutralization assay included the following controls 
(i) BKPyV only in PBS and (ii) cells only in PBS. Cultures were 
observed using a light microscope for CPE presence for 3 weeks.
BK polyomavirus CPE was assessed by three cell biologists 
of our working group. CPE inhibition was graded as negative, 
grade 0 (complete CPE), grade 1–2 as weak inhibition, grade 3 
as moderate inhibition, grade 4 as intermediate inhibition, and 
grade 5 as strong inhibition.
statistics
Differences among age groups were statistically evaluated. 
Statistical analyses were performed using Prism 4.0 software 
(GraphPad, San Diego, CA, USA). Data are presented as a per-
centage of the positive samples. The 95% confidence intervals of 
the percentage of positive samples are also reported. Differences 
among proportions were calculated by χ2 test for independence 
in the contingency tables. The small sample size was statistically 
analyzed using χ2 with Yates’ correction. The correlation between 
the OD value and BKPyV CPE was evaluated by non-parametric 
Spearman analysis, which indicates Spearman r and p values.
The serologic profile of serum antibody reactivity were ana-
lyzed with one way Anova analysis, and Newman–Keuls Multiple 
Comparison Test (OD mean, 95% CI).
resUlTs
In this study, a novel indirect ELISA with synthetic peptides as 
antigens was developed and set up to analyze the prevalence of 
serum antibodies against BKPyV in healthy adult subjects. Two 
peptides were selected from the amino acids in the VP1 L (VP1), 
which mimic unique BKPyV VP1 epitopes/antigens (Figure 1; 
Figure S1 in Supplementary Material). Computational analysis 
of the two peptides is characterized by their secondary and 
tertiary structures. Serum samples from HS were analyzed using 
the new indirect ELISA to detect specific IgG serum antibodies 
against BKPyV. BKPyV titers were determined by serial sera 
dilution, which was then analyzed again using indirect ELISA. 
Immunologic results were compared to data obtained from sera 
analyzed by the well-established HAI assay (19, 30), employed 
as control. Furthermore, serum samples, which tested BKPyV-
positive, were functionally assayed by inhibiting the viral CPE 
displayed in the permissive Vero cell line (19).
Peptide In Silico structural analysis
Computational analysis showed that the two linear pep-
tides (http://blast.ncbi.nlm.nih.gov; Figure  1; Figure S1 in 
Supplementary Material) are characterized by their secondary 
structure, as follows (PSIPRED server). Peptide VP1-L has a 
random coil secondary structure, whereas it does not contain 
any alpha helix or beta sheet domain (Figure  2A, on the left). 
Peptide VP1-M forms a stable secondary structure from a.a. 9 to 
a.a. 13, i.e., 9QKVHE13, where an alpha helix domain is present 
(Figure 2A, on the right).
Tertiary structures of BKPyV viral capsid protein VP1 
(Figures  2B–D), selected among computationally determined 
structures, presented C-scores of 0.51, with an estimated model 
accuracy: 0.78  ±  0.10 (TM-score), 5.5  ±  3.5Å (RMSD). For 
details, see Ref. (24–26). Mapping two linear peptides of the 
inferred protein structures showed that VP1-L does not fold in 
any structure type, whereas VP1-M folds in a short alpha helix 
domain (Figures 2B,C). The three-dimensional graph from L and 
M peptide structures, shows the specific amino acids exposed to 
the protein surface (Figure  2D), which may interact with the 
environment.
BKPyV antibodies Detection by indirect 
elisa
An indirect ELISA was setup using synthetic peptides in order to 
check whether human sera contain IgG antibodies, which react to 
BKPyV peptides and to determine the spread of BKPyV infection 
in humans. These synthetic peptides correspond to BKPyV VP1 
mimotopes. The unrelated human peptide hNPS was employed 
as a negative control (19).
In the first step of this investigation, indirect ELISA was used 
to test serum samples taken from HS ranging from 18 to 90 years 
old. The sera were diluted at 1/20 in order to react to BKPyV 
VP1 epitopes. Serum samples, which reacted to BKPyV VP1-L 
mimotope reached an overall prevalence of 80%. The same assay 
was then performed to detect IgG class serum antibodies against 
BKPyV VP1 epitopes, which are known as VP1-M. It turned out 
that serum samples reacted with the VP1 M peptide with the 
same prevalence, 80%, as had been detected previously for the 
VP1 L peptide. Conversely, seronegative samples for the BKPyV 
VP1 L peptide failed to react with BKPyV VP1 M epitopes. The 
exceptions were negligible and were represented by a few serum 
samples, which were found to be negative for VP1 L, while testing 
positive for VP1 M peptide, and vice-versa. The difference was 
not statistically significant (P > 0.05) (Table 1).
FigUre 2 | structural characteristics of VP1. (a) Secondary structures. Results of computational analysis carried out on BK polyomavirus (BKPyV) synthetic 
polypeptides (PSIPRED). Peptide VP1L, on the left, shows a random coiled domain, whereas peptide VP1M, on the right, contains an alpha helix domain.  
(B) Detailed view of VP1M peptide (blue) within the three-dimensional (3D) model of BKPyV VP1. Alpha helix domain is shifted to a.a. 126 and a.a. 127, being part of 
alpha helix structure (red) of the native protein. (c–D) 3D model of BK VP1 capsid protein. (c) VP1 L (random coiled) and VP1 M (small alpha helix domain) synthetic 
peptides are shown in pink and blue, respectively. (D) Mesh surface model of BKPyV VP1 with VP1L (pink) and VP1M (red) mapped in it. The peptide structures and 
their localization on the surface of the native protein are marked in pink (L) and red (M), respectively.
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Combining the BKPyV-positive sera, both for the VP1 L and 
VP1 M peptides, the overall prevalence was 72%, with no differ-
ence between male and female (Table 1). The two indirect ELISA 
tests, with two distinct VP peptides gave overlapping results, thus 
confirming the presence of anti-BKPyV VP antibodies in human 
sera from HS (Table 1).
A prevalence selection corresponding to 76, 81, 65, and 65%, 
within the cohorts ranging from 18 to 90 years old, was observed 
in subjects 18–39, 40–50, 51–61, and 62–90  years old, respec-
tively. Interestingly, serum antibodies prevalence against BKPyV 
VP declined in cohorts of individuals ranging from 51 to 61 and 
62 to 90 years old, with a percentage of 65% (Table 1).
BK polyomavirus-positive sera tested by indirect ELISA 
diluted at 1/20 had a general cutoff, range of 0.19 OD, using a 
spectrophotometric reading. This cutoff represents the dis-
criminatory value between BKPyV-negative samples (below 
OD 0.19) and BKPyV-positive samples (above OD 0.19). The 
positive control, represented by BKPyV hyperimmune rabbit 
serum, had an OD of up to 0.3, while the two JCPyV and SV40 
TaBle 1 | Prevalence of immunoglobulin g antibodies reacting to BK 
polyomavirus (BKPyV) viral protein mimotopes.
age (years) number of 
samples
Male (%) number of positive samples 
(prevalence %)
VP1-l VP1-M VP1 l + M
18–39 118 28 101 (86) 95 (80) 90 (76)
40–50 120 35 107 (89) 103 (86) 97 (81)
51–61 105 49 80 (76) 76 (72) 68 (65)
62–90 103 41 71 (69) 82 (73) 67 (65)
18–90 446 37 359 (80) 356 (80) 322 (72)
Human sera were from healthy adult subjects. Statistical analysis was performed 
using the chi-square test with Yates’ correction. The prevalence of BKPyV antibodies 
detected in the cohort of individuals 51–61 years old is statistically different from that 
revealed in the cohorts of subjects 18–39 years old (P = 0.02) and 40–50 years old 
(P = 0.01), respectively. The prevalence of BKPyV antibodies in the cohort of individuals 
62–90 years old is statistically different compared to that of the cohorts 18–39 years 
old (P = 0.018) and 40–50 years old (P = 0.008), respectively. Human sera were 
diluted 1/20. OD = 0.19 was used as a cutoff to identify BKPyV-positive samples. 
No different prevalence of BKPyV-positive samples was detected between male and 
female sera (P > 0.05).
FigUre 3 | serologic profile of human serum antibody reactivity to BKPyV mimotopes VP1 l (a), VP1 M (B), and VP1 l + M (c). Immunologic data are 
from serum samples from HS. Results are presented as values of optical density (OD) readings at λ 405 nm of serum samples diluted at 1:20, detected by the 
indirect enzyme-linked immunosorbent assay. In scatter dot plotting, each plot represents the dispersion of OD values to a mean level indicated by the line inside the 
scatter with SEM for each group of subjects analyzed.
TaBle 2 | Prevalence of serum igg antibodies against BK polyomavirus.
number of 
subject
Median 
age ± sD
Male 
(%)
number of positive samples (%) at 
the dilution indicated
1:16 1:32 1:64 1:128
87 69 ± 13 41 85 (98) 85 (98) 84 (97) 55 (63)
Analyzed using hemagglutination inhibition assay. Human sera were from healthy 
subjects. The dilution 1:128 has been chosen because lower dilutions, such as 1:32 or 
1:64, contain antibodies at higher concentration, which may give rise to false positive 
reaction; on the other hand, higher dilutions could carry antibodies at much lower 
concentration giving false negative reaction (19, 30).
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hyperimmune sera, employed as negative controls, had an OD of 
less than 0.01–0.02. The OD value was usually in the 0.01–0.02 
range, which is consistent with the OD for BKPyV-negative sera.
The human neuropeptide hNPS (33), which is unrelated to 
BKPyV, was employed as a negative control peptide in the ELISA 
experiments. Data indicate that this negative control peptide did 
not react with 322 BKPyV-positive sera, nor with 124 BKPyV-
negative samples. The OD value was usually in the 0.01–0.02 
range, which is consistent with the OD for BKPyV-negative sera.
In this investigation, BKPyV-positive sera (65%), which was 
detected both in 51- to 61 and 62- to 90-year-old subjects, was 
lower than that detected in the other cohorts of healthy individu-
als (Table 1). These differences are statistically significant when 
compared to other cohorts from different age groups (18–39; 
40–50 years old) (Table 1). The reduced prevalence of BKPyV-
positive sera in individuals 51–90 years old could be ascribed to 
natural age-dependent partial immune decline. Indeed, it is well 
established that the immune system physiologically declines with 
age, rendering individuals less responsive to infection. An alter-
native interpretation of the result, as suggested by other studies 
(34, 35) is that the low prevalence of BKPyV antibodies in sera 
from the elderly could depend on low BKPyV antibody stabil-
ity overtime. Serologic profiles of serum antibody reactivity to 
BKPyV mimotopes are presented in Figure 3. Serologic profile of 
serum antibody reactivity to BKPyV mimotopes VP1 L (A) and 
VP1 M (B) and VPs L + M (C). Data are OD values at 405 nm of 
serum samples diluted 1:20, detected in indirect ELISA. In scatter 
dot plotting, each plot represents the dispersion of OD values to 
a mean level indicated by the line inside the scatter with SEM 
for each age group of subjects analyzed (mean OD + SEM). The 
difference in OD mean values were not statistically significant in 
sera from HSs (P >  0.05; Anova analysis, and Newman–Keuls 
Multiple Comparison Test).
serum antibody Prevalence against 
BKPyV Determined by hai assay
A fraction of randomly chosen human sera (n = 87), which had 
been investigated by indirect ELISA were also analyzed using 
the well-established technique, known as HAI assay (19, 20, 30). 
Serum samples, serially twofold diluted from 1:16, 1:32, 1:64, to 
1:128, were analyzed by HAI to evaluate both the presence of 
antibodies against BKPyV and their titer.
The 1:128 dilution was chosen since other lower dilutions, 
such as 1:32 or 1:64 contain antibodies at higher concentrations, 
which may give rise to false positive reaction; on the other 
hand, higher dilutions could carry antibodies at much lower 
concentration giving false negative reaction (19, 20, 30). The 
seroprevalence of BKPyV-positive samples, diluted at 1:128, was 
63% (55/87). Seropositivity obtained with indirect ELISA on 
the same sera was 62% (54/87) (Table 2). The seroprevalence of 
BKPyV-positive in sera from HS, studied by HAI, did not differ 
statistically from that determined by indirect ELISA (P > 0.05). 
Interestingly, BKPyV-positive samples concordance from the 
two techniques was 98%.
Functional analysis of serum antibodies 
by neutralization activity Tested against 
BKPyV infection
An inhibition test was performed in order to check whether 
immune sera, containing antibodies against BKPyV, neutralized 
its infectivity. To this end, 15 immune sera, which ranged between 
a 0.19 and 0.65 OD reading, out of 322 BKPyV-positive samples, 
were selected to test their ability to inhibit the CPE in permissive 
BKPyV-infected Vero cells, along with 4 out 124 BKPyV-negative 
sera, with an OD of below 0.19, employed as control. In this 
FigUre 4 | inhibition of BK polyomavirus (BKPyV) cytopathic effect (cPe) in infected Vero cells by human serum samples. White arrows point normal 
cells, whereas black arrows indicate infected cells. CPE is characterized by the appearance of many vacuoles in the cytoplasm of infected Vero cells in the first 
phase, whereas the same cells are lysed and destroyed in the final step. (a) This panel represents (i) the positive control, i.e., uninfected Vero cells and (ii) the total 
CPE inhibition. In this image, single normal cells in the periphery and a cluster of them in the middle are shown. (a–e) Different degrees of CPE inhibition; there was 
a correlation between the optical density (OD) reading and the CPE inhibition activity of tested immune sera; the OD level was 0.65, 0.55, 0.45, 0.35, and 0.25, 
respectively. Sera with lower OD values inhibited less efficiently BKPyV CPE [from (a–e)]. Sera with mean OD values 0.65 inhibited BKPyV CPE completely (a), 
whereas serum samples with mean OD 0.15, BKPyV-negative samples show no CPE inhibition activity (F). The same (F) represents the negative control, i.e., BKPyV 
CPE in infected Vero cells. In this image, many cells show cytoplasmic vacuoles, while in the middle cells are lysed with the loss of the monolayer. Magnification 
200x.
FigUre 5 | inhibition of BK polyomavirus (BKPyV) cytopathic effect 
(cPe). Graph of the functional analysis of BKPyV human immune sera with 
neutralization activity. Immune sera with higher OD (Y-axis) inhibited more 
efficiently BKPyV CPE (X-axis) in infected Vero cell monolayers. Non-
parametric correlation Spearman analysis was performed: Spearman 
r = 0.988 and P < 0.0001.
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context, it is worth recalling that BKPyV CPE generates many 
cytoplasmic vacuoles in the first phase of the infection and then 
cell lysis of Vero monolayers (19). To avoid any possible cross-
reactivity, the 15 BKPyV-positive sera analyzed for their neutrali-
zation activity, were selected among SV40- and JCPyV-negative 
sera, as determined by indirect ELISA for SV40 VP (19) and HAI 
assay for JCPyV (unpublished results). The data are in agreement 
with previous reports. JCPyV- and SV40-positive sera showed no 
higher OD values toward VP1 L and VP1 M peptides than those, 
which tested negative. The neutralization effect of BKPyV-immune 
sera is apparent in infected cells when BKPyV CPE is abolished 
or hampered. The CPE inhibition test was performed by mixing 
the serum sample with BKPyV virions. Then, the mixture was 
employed as a viral inoculum to infect Vero cells. In inhibition 
experiments on BKPyV CPE, the positive and negative controls 
were (i) cells cultured without human serum and without BKPyV 
and (ii) cells infected with BKPyV, cultured without human serum, 
respectively. CPE inhibition in BKPyV-infected cells indicated 
that tested sera were able to neutralize BKPyV infectivity. Indeed, 
three sera with a mean OD = 0.65, taken from BKPyV-positive 
samples, completely inhibited BKPyV CPE (Figure 4A), while 12 
sera with a mean OD = 0.25–0.55, only partially inhibited BKPyV 
CPE, with a different degree (Figures 4B–E). Four samples with 
an OD < 0.19 did not inhibit BKPyV CPE (Figure 4F). There was 
a correlation between the OD reading and the CPE inhibition 
activity of the immune sera. Indeed, the correlation between OD 
and CPE inhibition is statistically significant (Spearman r = 0.988 
and P < 0.0001) (Figure 5).
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This assay detects functional antibodies to VP1 L that are 
capable of neutralizing BKPyV infectivity in tissue culture.
DiscUssiOn
Computational analysis of the two linear peptides VP1-L and 
VP1-M secondary structure and BKPyV VP1 tertiary structure 
revealed that VP1-L and VP1-M have secondary structures, 
which are similar to those found in the containing native protein, 
although the VP1-M alpha helix (9QKVHE13) domain is shifted 
to a shorter NH2-terminal alpha helix domain (a.a. 126–127) 
(Figure  2). The three dimensional mesh surface visualization 
(Figure 2) of the inferred protein tertiary structure, where the 
two linear peptides are mapped, showed that analyzed amino acid 
chains are exposed to the environment. These results may suggest 
that the two linear peptides VP1-L and VP1-M could resemble 
natural BKPyV linear epitopes constituting a docking site for 
serum antibody.
The three polyomaviruses BKPyV, JCPyV, and SV40 show a 
great a.a. sequence homology. Indeed, protein homology is 72% 
between BKPyV and JCPyV, 69% between BKPyV and SV40, and 
68% between JCPyV and SV40 (6, 19), respectively. High VLPs/
rVP1 cross-reactivity observed in previous immunologic tests, 
prompted us to develop and set up a BKPyV-specific indirect 
ELISA, with synthetic peptides as antigens, instead of VLP or 
soluble recombinant VP1.
Herein, human sera were analyzed for IgG antibodies react-
ing in indirect ELISA to two BKPyV VP1 mimotopes, VP1 L, 
and VP1 M. As a reaction control, hNPS, an unrelated human 
synthetic peptide, was employed as a negative control (19).
The objective of the present study was to investigate whether 
serum samples from HS ranging 18–90 years old carry BKPyV 
antibodies. Sera were analyzed using two different methods, 
an indirect ELISA with two mimotopes corresponding to VP1 
antigens and HAI assay (19). The two methods were employed to 
assay the specificity of tests and to confirm data obtained using 
the innovative ELISA with synthetic peptides as mimotopes of 
viral capsid proteins 1 (VP1).
These data indicate that the overall prevalence of BKPyV-VP1 
antibodies in humans, ranging from 18 to 90 years old, is 72%. 
No positive results were obtained with the human peptide hNPS 
used as a control (19).
In the second step of this investigation, human sera from 
HS were analyzed as control using the well-established HAI 
assay. This assay allows to detect serum antibodies against 
polyomavirus BKPyV, which abolish its agglutination prop-
erty. The seroprevalence of BKPyV-positive samples, diluted 
1:128, was 63% (55/87) in HS. HAI data were compared to 
those obtained by indirect ELISA. The seroprevalence of 
BKPyV-positive samples from HS determined by HAI does 
not significantly differ from that obtained using the indirect 
ELISA with synthetic peptides corresponding to VP1 epitopes 
(P > 0.05) (Table 1).
A neutralization activity test was then carried out as a func-
tional analysis on BKPyV-positive sera. It is important to note 
that BKPyV prevalence in human sera, as detected by this immu-
nological study, does not differ substantially from that obtained 
by using neutralization assay against BKPyV infectivity, which is 
considered the gold standard for measuring BKPyV antibodies in 
terms of neutralization activity (19).
When considered overall, these ELISA data indicate that, in 
normal individuals, natural BKPyV infection occurs at a high 
prevalence (72%), when compared with the low prevalence of 
infection spread over other new polyomaviruses, which range 
from 20 to 50% (36). The prevalence of anti-BKPyV serum 
antibodies increases with age, reaching 81% in the cohort from 
40 to 50  years old, with an increase of BKPyV antibody levels 
determined by OD readings.
It has been shown that BKPyV is present in the urine, stool, 
upper respiratory tract, and blood specimens in HS suggesting 
that different transmission routes are responsible for BKPyV 
infection.
Functional analysis data on BKPyV infectivity inhibition 
obtained with immune sera from normal subjects are of inter-
est. There is a correlation between the grade of BKPyV infec-
tion inhibitory effect by immune sera and antibody level of as 
determined by OD readings. A higher concentration of serum 
antibodies gave a stronger inhibition effect on BKPyV infection 
in tissue cultures.
Since the selected BKPyV-immune sera were JCPyV- and 
SV40-negative, there is no possible cross-inhibition effect due 
to antibodies against the two closely related polyomaviruses. 
Indeed, BKPyV and JCPyV are ubiquitous in the human popula-
tion with a prevalence of up to 90 and 60%, respectively (2, 6), 
whereas SV40-positive sera account for approximately 20% of 
human samples (19).
In order to further examine BKPyV-positive samples serology, 
endpoint titers were determined using indirect ELISA. The high-
est endpoint titer was observed at a 1/160 dilution for both VP 1L 
and VP1 M peptides.
In conclusion, the innovative indirect ELISA with BKPyV 
VP1 mimotopes reported herein seems to be a useful new 
method for detecting specific IgG antibodies against this virus 
in human sera, without cross-reactivity with other small DNA 
tumor viruses, such as the closely related SV40 and JCPyV 
polyomaviruses.
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